SCHEMBL4904324

SCHEMBL4904324

Cc1cc(C)n(-c2nc(Nc3ccc4c(c3)OCO4)c3ccccc3n2)n1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 11/20 0.69
KMT2A Q03164 11/20 0.69
MAPT P10636 10/20 0.69
MAPK1 P28482 5/20 0.69
CASP1 P29466 2/20 0.69
L3MBTL1 Q9Y468 2/20 0.69
CASP7 P55210 1/20 0.69
TGFBR1 P36897 1/20 0.64
SHMT2 P34897 1/20 0.57
ALOX15 P16050 6/20 0.55
ALDH1A1 P00352 6/20 0.55
HTT P42858 4/20 0.55
NPSR1 Q6W5P4 2/20 0.55
HSD17B10 Q99714 6/20 0.52
LMNA P02545 3/20 0.52
HPGD P15428 3/20 0.52
GAA P10253 2/20 0.52
ABL1 P00519 1/20 0.52
LCK P06239 1/20 0.52
FYN P06241 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4908142 0.83 TDP1 (0.64) MEN1KMT2AMAPTMAPK1L3MBTL1
SCHEMBL4910531 0.82 TDP1 (0.51) MEN1KMT2AMAPTMAPK1CASP1
SCHEMBL4907560 0.82 KDM4E (0.64) MEN1KMT2AMAPTALOX15ALDH1A1
SCHEMBL4914786 0.81 TDP1 (0.55) MEN1KMT2AMAPTALOX15ALDH1A1
SCHEMBL4904189 0.81 NPY5R (0.57) MEN1KMT2AMAPTALOX15ALDH1A1
SCHEMBL4911556 0.80 POLB (0.61) MEN1KMT2AMAPTL3MBTL1TGFBR1
SCHEMBL4908031 0.80 HTR2A (0.57) MEN1KMT2AMAPTALOX15ALDH1A1
SCHEMBL4913824 0.80 BCL6 (0.62) MEN1KMT2AMAPTALOX15ALDH1A1
SCHEMBL4908834 0.80 TDP1 (0.54) MEN1KMT2AMAPTALOX15ALDH1A1
SCHEMBL4911120 0.78 MAPT (0.62) MEN1KMT2AMAPTMAPK1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1861388-B1 POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE SANIONA AS (DK) 2017-07-05 EP claimed
US-8252806-B2 2-(3,5-Dimethyl-pyrazol-1-yl)-quinazolin-4-yl]-propylamine; 2-(3,5-Dimethyl-pyrazol-1-yl)-quinazolin-4-yl]-(4-morpholin-4-yl-phenyl)-amine; respiratory diseases, epilepsy, convulsions, seizures, gastrointestinal dysfunction, ischaemia, psychosis, schizophrenia, anxiety, depression, Alzheimer's disease NEUROSEARCH A/S (DK) 2012-08-28 US claimed
US-20080275045-A1 Potassium Channel Modulating Agents and Their Medical Use NEUROSEARCH A/S (DK) 2008-11-06 US claimed
EP-1861388-A1 POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE NeuroSearch A/S (DK) 2007-12-05 EP claimed
WO-2006097441-A1 POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2006-09-21 WO claimed
EP-1861388-B1 POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE SANIONA AS (DK) 2017-07-05 EP disclosed
US-8252806-B2 2-(3,5-Dimethyl-pyrazol-1-yl)-quinazolin-4-yl]-propylamine; 2-(3,5-Dimethyl-pyrazol-1-yl)-quinazolin-4-yl]-(4-morpholin-4-yl-phenyl)-amine; respiratory diseases, epilepsy, convulsions, seizures, gastrointestinal dysfunction, ischaemia, psychosis, schizophrenia, anxiety, depression, Alzheimer's disease NEUROSEARCH A/S (DK) 2012-08-28 US disclosed
US-20080275045-A1 Potassium Channel Modulating Agents and Their Medical Use NEUROSEARCH A/S (DK) 2008-11-06 US disclosed
EP-1861388-A1 POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE NeuroSearch A/S (DK) 2007-12-05 EP disclosed
WO-2006097441-A1 POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2006-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275045-A1 Potassium Channel Modulating Agents and Their Medical Use KCND2, KCNN3, KCNJ2 MEN1 2356/4885KMT2A 1232/4885MAPT 981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.